

SCORE Search Results Details for Application 10552515 and Search Result 20080624_135912_us-10-552-515-1_copy_157_933.szlm.rag.

[Score Home Page](#) [Retrieve Application List](#) [SCORE System Overview](#) [SCORE FAQ](#) [Comments / Suggestions](#)

This page gives you Search Results detail for the Application 10552515 and Search Result 20080624_135912_us-10-552-515-1_copy_157_933.szlm.rag.

[Go Back to previous page](#)

GenCore version 6.2.1
Copyright (c) 1993 - 2008 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: June 24, 2008, 15:35:29 ; Search time 326 Seconds
(without alignments)
1434.542 Million cell updates/sec

Title: US-10-552-515-1_COPY_157_933

Perfect score: 4123

Sequence: 1 QQDVQDGNTTVHYALLSASW.....SELSSHWTPTVPKASQLQQ 777

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 3405708 seqs, 601879884 residues

Total number of hits satisfying chosen parameters: 936429

Minimum DB seq length: 8

Maximum DB seq length: 20

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_200711:*

- 1: geneseqp1980s:*
- 2: geneseqp1990s:*
- 3: geneseqp2000:*
- 4: geneseqp2001:*
- 5: geneseqp2002:*
- 6: geneseqp2003a:*
- 7: geneseqp2003b:*

```

8: geneseqp2004a:*
9: geneseqp2004b:*
10: geneseqp2005:*
11: geneseqp2006:*
12: geneseqp2007:*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query				Description
		Match	Length	DB	ID	
1	65	1.6	20	4	ABB37977	Abb37977 Peptide #
2	65	1.6	20	4	AAM31389	Aam31389 Peptide #
3	65	1.6	20	4	ABG52827	Abg52827 Human liv
4	65	1.6	20	4	AAM18857	Aam18857 Peptide #
5	65	1.6	20	5	ABG40906	Abg40906 Human pep
6	52	1.3	15	6	ABJ54930	Abj54930 151P3D4 c
7	52	1.3	15	6	ABJ55780	Abj55780 151P3D4 c
8	52	1.3	15	6	ABJ54446	Abj54446 151P3D4 c
9	52	1.3	15	6	ABJ56387	Abj56387 151P3D4 c
10	48	1.2	9	8	ADT77672	Adt77672 Splice va
11	48	1.2	15	6	ABJ55714	Abj55714 151P3D4 c
12	48	1.2	15	6	ABJ54418	Abj54418 151P3D4 c
13	48	1.2	15	6	ABJ54982	Abj54982 151P3D4 c
14	48	1.2	15	6	ABJ56325	Abj56325 151P3D4 c
15	47	1.1	15	6	ABJ56284	Abj56284 151P3D4 c
16	47	1.1	15	6	ABJ54968	Abj54968 151P3D4 c
17	47	1.1	15	6	ABJ54396	Abj54396 151P3D4 c
18	47	1.1	15	6	ABJ55784	Abj55784 151P3D4 c
19	47	1.1	20	4	AAB90144	Aab90144 Factor VI
20	47	1.1	20	5	AAM48068	Aam48068 RNA bindi
21	47	1.1	20	7	ABR82328	Abr82328 Clone AD
22	47	1.1	20	7	ABR82336	Abr82336 Factor X
23	46.5	1.1	18	2	AAR82864	Aar82864 N-termina
24	46	1.1	9	8	ADT77666	Adt77666 Splice va
25	46	1.1	15	5	ABJ14449	Abj14449 Human 125
26	46	1.1	15	5	ABJ14602	Abj14602 Human 125
27	46	1.1	15	5	ABJ14448	Abj14448 Human 125
28	46	1.1	15	5	ABJ14731	Abj14731 Human 125
29	46	1.1	15	8	ADL21968	Adl21968 125P5C8 p
30	46	1.1	15	8	ADL21686	Adl21686 125P5C8 p
31	46	1.1	15	8	ADL21839	Adl21839 125P5C8 p
32	46	1.1	15	8	ADL21685	Adl21685 125P5C8 p
33	45.5	1.1	20	6	ADD12327	Add12327 PDZ ligan
34	45	1.1	20	6	ADC15450	Adc15450 Human bre

35	45	1.1	20	6	ADC15451	Adc15451 Human bre
36	44	1.1	9	8	ADT77673	Adt77673 Splice va
37	44	1.1	13	2	AAW70925	Aaw70925 CDR3 of t
38	44	1.1	16	8	ADW68208	Adw68208 Rabbit an
39	44	1.1	16	8	ADO79153	Ado79153 Rabbit an
40	44	1.1	18	5	ABB78503	Abb78503 GAGP rela
41	44	1.1	18	8	ADU09291	Adu09291 Gum arabi
42	44	1.1	19	3	AAY79347	Aay79347 Equine in
43	44	1.1	19	5	ABB78401	Abb78401 Gum arabi
44	44	1.1	19	5	ABB78463	Abb78463 Gum arabi
45	44	1.1	19	5	ABB78465	Abb78465 Gum arabi

ALIGNMENTS

RESULT 1

ABB37977

ID ABB37977 standard; peptide; 20 AA.

XX

AC ABB37977;

XX

DT 04-FEB-2002 (first entry)

XX

DE Peptide #5483 encoded by human foetal liver single exon probe.

XX

KW Human; foetal liver; gene expression; single exon nucleic acid probe.

XX

OS Homo sapiens.

XX

PN WO200157277-A2.

XX

PD 09-AUG-2001.

XX

PF 30-JAN-2001; 2001WO-US000669.

XX

PR 04-FEB-2000; 2000US-0180312P.

PR 26-MAY-2000; 2000US-0207456P.

PR 30-JUN-2000; 2000US-00608408.

PR 03-AUG-2000; 2000US-00632366.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

XX

PA (MOLE-) MOLECULAR DYNAMICS INC.

XX

PI Penn SG, Hanzel DK, Chen W, Rank DR;

XX

DR WPI; 2001-483447/52.

XX

PT Human genome-derived single exon nucleic acid probes useful for analyzing
 PT gene expression in human fetal liver.

XX

PS Claim 27; SEQ ID NO 30612; 639pp + Sequence Listing; English.

XX

CC The invention relates to a single exon nucleic acid probe for measuring
 CC human gene expression in a sample derived from human foetal liver. The
 CC single exon nucleic acid probes may be used for predicting, measuring and
 CC displaying gene expression in samples derived from human fetal liver. The
 CC present sequence is a peptide encoded by a single exon nucleic acid probe
 CC of the invention. Note: The sequence data for this patent did not form
 CC part of the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 20 AA;

Query Match 1.6%; Score 65; DB 4; Length 20;
 Best Local Similarity 60.0%; Pred. No. 45;
 Matches 12; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 437 IFQFVNFYSSPVYIAFFKGR 456
 : : ||| || |:|||||||
 Db 1 LLKFVNAYSPIFYVAFFKGR 20

RESULT 2

AAM31389

ID AAM31389 standard; protein; 20 AA.

XX

AC AAM31389;

XX

DT 17-OCT-2001 (first entry)

XX

DE Peptide #5426 encoded by probe for measuring placental gene expression.

XX

KW Probe; microarray; human; placenta; antenatal diagnosis;
 KW genetic disorder.

XX

OS Homo sapiens.

XX

PN WO200157272-A2.

XX

PD 09-AUG-2001.

XX

PF 30-JAN-2001; 2001WO-US000663.

XX

PR 04-FEB-2000; 2000US-0180312P.

PR 26-MAY-2000; 2000US-0207456P.

PR 30-JUN-2000; 2000US-00608408.
 PR 03-AUG-2000; 2000US-00632366.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.

XX
 PA (MOLE-) MOLECULAR DYNAMICS INC.
 XX

PI Penn SG, Hanzel DK, Chen W, Rank DR;

XX
 DR WPI; 2001-488897/53.

XX
 PT Human genome-derived single exon nucleic acid probes useful for analyzing
 gene expression in human placenta.

XX
 PS Claim 27; SEQ ID NO 31658; 654pp; English.
 XX

CC The present invention relates to single exon nucleic acid probes (SENP:
 CC see AAI31315-AAI57546). The present sequence is a peptide encoded by one
 CC such probe. The probes are useful for producing a microarray for
 CC predicting, measuring and displaying gene expression in samples derived
 CC from human placenta. The probes are useful for antenatal diagnosis of
 CC human genetic disorders

XX
 SQ Sequence 20 AA;

Query Match 1.6%; Score 65; DB 4; Length 20;
 Best Local Similarity 60.0%; Pred. No. 45;
 Matches 12; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 437 IFQFVNFYSSPVYIAFFKGR 456
 : : ||| || |:|||||||
 Db 1 LLKFVNAYSPIFYVAFFKGR 20

RESULT 3
 ABG52827
 ID ABG52827 standard; peptide; 20 AA.

XX
 AC ABG52827;
 XX
 DT 25-FEB-2003 (first entry)

XX
 DE Human liver peptide, SEQ ID No 31475.

XX
 KW Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
 KW hypercholesterolaemia; coronary heart disease.

XX
 OS Homo sapiens.

XX
 PN WO200157273-A2.

XX
 PD 09-AUG-2001.

XX
 PF 30-JAN-2001; 2001WO-US000664.

XX
 PR 04-FEB-2000; 2000US-0180312P.
 PR 26-MAY-2000; 2000US-0207456P.
 PR 30-JUN-2000; 2000US-00608408.
 PR 03-AUG-2000; 2000US-00632366.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.

XX
 PA (MOLE-) MOLECULAR DYNAMICS INC.

XX
 PI Penn SG, Hanzel DK, Chen W, Rank DR;

XX
 DR WPI; 2001-488898/53.

XX
 PT Human genome-derived single exon nucleic acid probes useful for analyzing
 gene expression in human adult liver.

XX
 PS Claim 27; SEQ ID NO 31475; 658pp; English.

XX
 CC The invention relates to a single exon nucleic acid probe (SENP) (I) for
 CC measuring human gene expression in a sample derived from human adult
 CC liver, comprising one of 13109 defined nucleotide sequences given in the
 CC specification (or complements/ fragments). The probe hybridises at high
 CC stringency to a nucleic acid molecule expressed in the human adult liver.
 CC (I) may be used for predicting, measuring and displaying gene expression
 CC in samples derived from human adult liver. The genes identified may be
 CC involved in genetic liver diseases such as cirrhosis,
 CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
 CC associated with coronary heart disease. ABG47348-ABG59930 represent human
 CC liver single exon encoded peptides of the invention. Note: The sequence
 CC information for this patent does not appear in the printed specification
 CC but was obtained in electronic format directly from WIPO at
 CC ftp://wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 20 AA;

Query Match	1.6%	Score	65	DB	4	Length	20
Best Local Similarity	60.0%	Pred. No.	45				
Matches	12	Conservative	3	Mismatches	5	Indels	0
Gaps	0						

Qy 437 IFQFVNFYSSPVYIAFFKGR 456
 : :||| || |:|||||

Db 1 LLKFVNAYSPIFYVAFFKGR 20

RESULT 4

AAM18857

ID AAM18857 standard; protein; 20 AA.

XX

AC AAM18857;

XX

DT 12-OCT-2001 (first entry)

XX

DE Peptide #5291 encoded by probe for measuring cervical gene expression.

XX

KW Probe; human; microarray; gene expression; cervical epithelial cell;
cervical cancer.

XX

OS Homo sapiens.

XX

PN WO200157278-A2.

XX

PD 09-AUG-2001.

XX

PF 30-JAN-2001; 2001WO-US000670.

XX

PR 04-FEB-2000; 2000US-0180312P.

PR 26-MAY-2000; 2000US-0207456P.

PR 30-JUN-2000; 2000US-00608408.

PR 03-AUG-2000; 2000US-00632366.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

XX

PA (MOLE-) MOLECULAR DYNAMICS INC.

XX

PI Penn SG, Hanzel DK, Chen W, Rank DR;

XX

DR WPI; 2001-488901/53.

XX

PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human cervical epithelial cells.

XX

PS Claim 27; SEQ ID NO 23683; 487pp; English.

XX

CC The present invention relates to human single exon nucleic acid probes
CC (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC can be used to produce a single exon microarray, which can be used for
CC measuring human gene expression in a sample derived from human cervical
CC epithelial cells. By measuring gene expression, the probes are therefore

CC useful in grading and/or staging of diseases of the cervix, notably
 CC cervical cancer. Note: The sequence data for this patent did not form
 CC part of the printed specification, but was obtained in electronic format
 CC directly from WIPO at [ftp.wipo.int/pub/published_pct_sequences](ftp://ftp.wipo.int/pub/published_pct_sequences)

XX

SQ Sequence 20 AA;

Query Match 1.6%; Score 65; DB 4; Length 20;
 Best Local Similarity 60.0%; Pred. No. 45;
 Matches 12; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 437 IFQFVNFYSSPVYIAFFKGR 456
 : :||| || |:|||||
 Db 1 LLKFVNAYSPIFYVAFFKGR 20

RESULT 5

ABG40906

ID ABG40906 standard; peptide; 20 AA.

XX

AC ABG40906;

XX

DT 19-AUG-2002 (first entry)

XX

DE Human peptide encoded by genome-derived single exon probe SEQ ID 30571.

XX

KW Human; single exon probe; asthma; lung cancer; COPD; ILD;
 KW chronic obstructive pulmonary disease; interstitial lung disease;
 KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
 KW tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
 KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
 KW pulmonary histiocytosis; lymphangioleiomyomatosis; Karagener syndrome;
 KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
 KW primary ciliary dyskinesia; pulmonary hypertension;
 KW hyaline membrane disease.

XX

OS Homo sapiens.

XX

PN WO200186003-A2.

XX

PD 15-NOV-2001.

XX

PF 30-JAN-2001; 2001WO-US000665.

XX

PR 04-FEB-2000; 2000US-0180312P.

PR 26-MAY-2000; 2000US-0207456P.

PR 30-JUN-2000; 2000US-00608408.

PR 03-AUG-2000; 2000US-00632366.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

XX

PA (MOLE-) MOLECULAR DYNAMICS INC.

XX

PI Penn SG, Hanzel DK, Chen W, Rank DR;

XX

DR WPI; 2002-114183/15.

XX

PT Spatially-addressable set of single exon nucleic acid probes, used to
PT measure gene expression in human lung samples.

XX

PS Claim 27; SEQ ID NO 30571; 634pp; English.

XX

CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human lung comprising single exon nucleic acid probes having one of
CC 12614 nucleic acid sequences mentioned in the specification, or their
CC complements or the 12387 open reading frames derived from the 12614
CC probes. Also included are a microarray comprising the novel set of probes
CC ; the novel set of probes which hybridise at high stringency to a nucleic
CC acid expressed in the human lung; measuring gene expression in a sample
CC derived from human lung, comprising (a) contacting the array with a
CC collection of detectably labeled nucleic acids derived from human lung
CC mRNA, and (b) measuring the label detectably bound to each probe of the
CC array; identifying exons in a eukaryotic genome, comprising (a)
CC algorithmically predicting at least one exon from genomic sequences of
CC the eukaryote; and (b) detecting specific hybridisation of detectably
CC labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC having a fragment identical to the predicted exon, the probe is included
CC in the above mentioned microarray; assigning exons to a single gene,
CC comprising (a) identifying exons from genomic sequence by the method
CC above and (b) measuring the expression of each of the exons in several
CC tissues and/or cell types using hybridisation to a single exon
CC microarrays having a probe with the exon, where a common pattern of
CC expression of the exons in the tissues and/or cell types indicates that
CC the exons should be assigned to a single gene; a peptide comprising one
CC of 12011 sequences, mentioned in the specification, or encoded by the
CC probes/open reading frames (ORF). The probes are used for gene expression
CC analysis, and for identifying exons in a gene, particularly using human
CC lung derived mRNA and for the study of lung diseases such as asthma, lung
CC cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC histiocytosis, lymphangioleiomyomatosis, pulmonary alveolar proteinosis,
CC Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC dyskinesis, pulmonary hypertension and hyaline membrane disease. The
CC present sequence is a peptide/protein encoded by a single exon probe of

CC the invention. Note: The sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 20 AA;

Query Match 1.6%; Score 65; DB 5; Length 20;
 Best Local Similarity 60.0%; Pred. No. 45;
 Matches 12; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 437 IFQFVNFYSSPVYIAFFKGR 456
 : :||| || |:|||||
 Db 1 LLKFVNAYSPIFYVAFFKGR 20

RESULT 6
 ABJ54930
 ID ABJ54930 standard; peptide; 15 AA.

XX
 AC ABJ54930;
 XX
 DT 16-OCT-2003 (first entry)

XX
 DE 151P3D4 cancer gene related HLA peptide #12750.
 XX

KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoural; cancer;
 KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
 KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.
 XX

OS Homo sapiens.

XX
 PN WO200283860-A2.

XX
 PD 24-OCT-2002.

XX
 PF 09-APR-2002; 2002WO-US011644.

XX
 PR 10-APR-2001; 2001US-0282739P.
 PR 25-APR-2001; 2001US-0286630P.

XX
 PA (AGEN-) AGENSYS INC.

XX
 PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
 PI Morrison RK, Ge W, Jakobovits A;

XX
 DR WPI; 2003-167091/16.

XX
 PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
 PT cellular immune response, or for diagnosing, prognosing, preventing or

PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer or carcinoma.

XX
PS Claim 13; Page 287; 426pp; English.

CC The invention relates to a novel composition comprising a substance that CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or CC a molecule that is modulated by the 151P3D4 protein, where the status of CC a cell that expresses the 151P3D4 protein is modulated. The novel CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting CC a humoral or cellular immune response. The 151P3D4 genes and proteins CC are also useful for diagnosing, prognosis, preventing or treating CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or CC bronchial cancer, breast cancer or carcinoma. This sequence represents a CC human leukocyte antigen peptide relating to the 151P3D4 composition of CC the invention

XX
SQ Sequence 15 AA;

Query Match	1.3%	Score	52	DB	6	Length	15
Best Local Similarity	60.0%	Pred. No.	7.3e+02				
Matches	9	Conservative	2	Mismatches	4	Indels	0
						Gaps	0

QY 456 RFVGYPGNYHTLFGV 470
 ||||:| | |:||
Db 1 RFVGFPDKKKHKLGV 15

RESULT 7

ABJ55780

ID ABJ55780 standard; peptide; 15 AA.

XX

AC ABJ55780;

XX

DT 16-OCT-2003 (first entry)

XX

DE 151P3D4 cancer gene related HLA peptide #13600.

XX

KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer; KW cellular immune response; adenocarcinoma; bladder; colorectal; lung; KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.

XX

OS Homo sapiens.

XX

PN WO200283860-A2.

XX

PD 24-OCT-2002.

XX

PF 09-APR-2002; 2002WO-US011644.

XX
 PR 10-APR-2001; 2001US-0282739P.
 PR 25-APR-2001; 2001US-0286630P.
 XX
 PA (AGEN-) AGENSYS INC.
 XX
 PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
 PI Morrison RK, Ge W, Jakobovits A;
 XX
 DR WPI; 2003-167091/16.
 XX
 PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
 PT cellular immune response, or for diagnosing, prognosing, preventing or
 PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
 PT or carcinoma.
 XX
 PS Claim 13; Page 303; 426pp; English.
 XX
 CC The invention relates to a novel composition comprising a substance that
 CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
 CC a molecule that is modulated by the 151P3D4 protein, where the status of
 CC a cell that expresses the 151P3D4 protein is modulated. The novel
 CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
 CC a humoral or cellular immune response. The 151P3D4 genes and proteins
 CC are also useful for diagnosing, prognosing, preventing or treating
 CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
 CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
 CC human leukocyte antigen peptide relating to the 151P3D4 composition of
 CC the invention
 XX
 SQ Sequence 15 AA;

Query Match 1.3%; Score 52; DB 6; Length 15;
 Best Local Similarity 60.0%; Pred. No. 7.3e+02;
 Matches 9; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 456 RFVGYPGNYHTLFGV 470
 ||||:|| | |:|||
 Db 1 RFVGFPDKHKLYGV 15

RESULT 8
 ABJ54446
 ID ABJ54446 standard; peptide; 15 AA.
 XX
 AC ABJ54446;
 XX
 DT 16-OCT-2003 (first entry)
 XX

DE 151P3D4 cancer gene related HLA peptide #12266.

XX

KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoural; cancer;
 KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
 KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.

XX

OS Homo sapiens.

XX

PN WO200283860-A2.

XX

PD 24-OCT-2002.

XX

PF 09-APR-2002; 2002WO-US011644.

XX

PR 10-APR-2001; 2001US-0282739P.

PR 25-APR-2001; 2001US-0286630P.

XX

PA (AGEN-) AGENSYN INC.

XX

PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;

PI Morrison RK, Ge W, Jakobovits A;

XX

DR WPI; 2003-167091/16.

XX

PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
 PT cellular immune response, or for diagnosing, prognosing, preventing or
 PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
 PT or carcinoma.

XX

PS Claim 13; Page 278; 426pp; English.

XX

CC The invention relates to a novel composition comprising a substance that
 CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
 CC a molecule that is modulated by the 151P3D4 protein, where the status of
 CC a cell that expresses the 151P3D4 protein is modulated. The novel
 CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
 CC a humoral or cellular immune response. The 151P3D4 genes and proteins
 CC are also useful for diagnosing, prognosing, preventing or treating
 CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
 CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
 CC human leukocyte antigen peptide relating to the 151P3D4 composition of
 CC the invention

XX

SQ Sequence 15 AA;

Query Match 1.3%; Score 52; DB 6; Length 15;

Best Local Similarity 60.0%; Pred. No. 7.3e+02;

Matches 9; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 456 RFVGYPGNYHTLFGV 470

||||:| | |:||

Db 1 RFVGFDPDKHKLYGV 15

RESULT 9

ABJ56387

ID ABJ56387 standard; peptide; 15 AA.

XX

AC ABJ56387;

XX

DT 16-OCT-2003 (first entry)

XX

DE 151P3D4 cancer gene related HLA peptide #14207.

XX

KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;
KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.

XX

OS Homo sapiens.

XX

PN WO200283860-A2.

XX

PD 24-OCT-2002.

XX

PF 09-APR-2002; 2002WO-US011644.

XX

PR 10-APR-2001; 2001US-0282739P.

PR 25-APR-2001; 2001US-0286630P.

XX

PA (AGEN-) AGENSYN INC.

XX

PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
PI Morrison RK, Ge W, Jakobovits A;

XX

DR WPI; 2003-167091/16.

XX

PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosis, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.

XX

PS Claim 13; Page 314; 426pp; English.

XX

CC The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a cell that expresses the 151P3D4 protein is modulated. The novel
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting

CC a humoural or cellular immune response. The 151P3D4 genes and proteins
 CC are also useful for diagnosing, prognosing, preventing or treating
 CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
 CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
 CC human leukocyte antigen peptide relating to the 151P3D4 composition of
 CC the invention

XX

SQ Sequence 15 AA;

Query Match 1.3%; Score 52; DB 6; Length 15;
 Best Local Similarity 60.0%; Pred. No. 7.3e+02;
 Matches 9; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 456 RFVGVPGNYHTLFGV 470
 ||||:| |||:||
 Db 1 RFVGFPDKKHLYGV 15

RESULT 10

ADT77672

ID ADT77672 standard; peptide; 9 AA.

XX

AC ADT77672;

XX

DT 13-JAN-2005 (first entry)

XX

DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.

XX

KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;
 prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.

XX

OS Homo sapiens.

XX

PN WO2004092213-A1.

XX

PD 28-OCT-2004.

XX

PF 05-APR-2004; 2004WO-US010588.

XX

PR 08-APR-2003; 2003US-0461399P.

XX

PA (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX

PI Pastan I, Bera TK, Lee B;

XX

DR WPI; 2004-758338/74.

XX

PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
 PT encoding nucleic acid molecule for diagnosing, preventing or treating

PT cancer, especially prostate cancer.

XX

PS Disclosure; SEQ ID NO 9; 88pp; English.

XX

CC The present sequence is that of a predicted epitope of human splice
 CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
 CC is predicted to bind HLA2-01 and was identified using an HLA binding
 CC motif program. It corresponds to amino acids 403-411 of SV-NGEP.
 CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
 CC acids of SV-NGEP which specifically bind to an antibody that specifically
 CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
 CC claimed. The invention provides methods for: detecting prostate cancer in
 CC a subject by contacting a sample with an antibody that specifically binds
 CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
 CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
 CC producing an immune response against a cell expressing SV-NGEP, for
 CC example in a subject with prostate cancer, by administering SV-NGEP
 CC polypeptide or polynucleotide to produce an immune response that
 CC decreases growth of the prostate cancer; inhibiting the growth of a
 CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
 CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
 CC these with the malignant cell; and inhibiting the growth of a malignant
 CC cell by contact with an antibody that specifically binds SV-NGEP, where
 CC the antibody is linked to a chemotherapeutic agent or toxin.

XX

SQ Sequence 9 AA;

Query Match	1.2%	Score	48	DB	8	Length	9
Best Local Similarity	100.0%	Pred. No.	2.9e+06				
Matches	9	Conservative	0	Mismatches	0	Indels	0
						Gaps	0

Qy 247 WLLSSACAL 255

|||||||

Db 1 WLLSSACAL 9

RESULT 11

ABJ55714

ID ABJ55714 standard; peptide; 15 AA.

XX

AC ABJ55714;

XX

DT 16-OCT-2003 (first entry)

XX

DE 151P3D4 cancer gene related HLA peptide #13534.

XX

KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoural; cancer;
 KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
 KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.

XX
OS Homo sapiens.

XX
PN WO200283860-A2.

XX
PD 24-OCT-2002.

XX
PF 09-APR-2002; 2002WO-US011644.

XX
PR 10-APR-2001; 2001US-0282739P.
PR 25-APR-2001; 2001US-0286630P.

XX
PA (AGEN-) AGENSYN INC.

XX
PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
PI Morrison RK, Ge W, Jakobovits A;

XX
DR WPI; 2003-167091/16.

XX
PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.

XX
PS Claim 13; Page 302; 426pp; English.

XX
CC The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a cell that expresses the 151P3D4 protein is modulated. The novel
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoral or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC human leukocyte antigen peptide relating to the 151P3D4 composition of
CC the invention

XX
SQ Sequence 15 AA;

Query Match 1.2%; Score 48; DB 6; Length 15;
Best Local Similarity 57.1%; Pred. No. 2e+03;
Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 456 RFVGYPGNYHTLFG 469
||||:|| | :|

Db 2 RFVGFPDKHKLYG 15

RESULT 12

ABJ54418

ID ABJ54418 standard; peptide; 15 AA.

XX

AC ABJ54418;

XX

DT 16-OCT-2003 (first entry)

XX

DE 151P3D4 cancer gene related HLA peptide #12238.

XX

KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoural; cancer;

KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;

KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.

XX

OS Homo sapiens.

XX

PN WO200283860-A2.

XX

PD 24-OCT-2002.

XX

PF 09-APR-2002; 2002WO-US011644.

XX

PR 10-APR-2001; 2001US-0282739P.

PR 25-APR-2001; 2001US-0286630P.

XX

PA (AGEN-) AGENSYS INC.

XX

PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;

PI Morrison RK, Ge W, Jakobovits A;

XX

DR WPI; 2003-167091/16.

XX

PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.

XX

PS Claim 13; Page 278; 426pp; English.

XX

CC The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a cell that expresses the 151P3D4 protein is modulated. The novel
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoral or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC human leukocyte antigen peptide relating to the 151P3D4 composition of

CC the invention

XX

SQ Sequence 15 AA;

Query Match 1.2%; Score 48; DB 6; Length 15;
 Best Local Similarity 57.1%; Pred. No. 2e+03;
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 456 RFVGYPGNYHTLFG 469

||||:| | :|

Db 2 RFVGFPDKHKLYG 15

RESULT 13

ABJ54982

ID ABJ54982 standard; peptide; 15 AA.

XX

AC ABJ54982;

XX

DT 16-OCT-2003 (first entry)

XX

DE 151P3D4 cancer gene related HLA peptide #12802.

XX

KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoural; cancer;
 KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
 KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.

XX

OS Homo sapiens.

XX

PN WO200283860-A2.

XX

PD 24-OCT-2002.

XX

PF 09-APR-2002; 2002WO-US011644.

XX

PR 10-APR-2001; 2001US-0282739P.

PR 25-APR-2001; 2001US-0286630P.

XX

PA (AGEN-) AGENSYN INC.

XX

PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
 PI Morrison RK, Ge W, Jakobovits A;

XX

DR WPI; 2003-167091/16.

XX

PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
 PT cellular immune response, or for diagnosing, prognosing, preventing or
 PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
 PT or carcinoma.

XX
 PS Claim 13; Page 288; 426pp; English.
 XX

CC The invention relates to a novel composition comprising a substance that modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or a molecule that is modulated by the 151P3D4 protein, where the status of a cell that expresses the 151P3D4 protein is modulated. The novel compositions, or the 151P3D4 proteins and genes, are useful for eliciting a humoral or cellular immune response. The 151P3D4 genes and proteins are also useful for diagnosing, prognosis, preventing or treating cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or bronchial cancer, breast cancer or carcinoma. This sequence represents a human leukocyte antigen peptide relating to the 151P3D4 composition of the invention
 XX

SQ Sequence 15 AA;

Query Match 1.2%; Score 48; DB 6; Length 15;
 Best Local Similarity 57.1%; Pred. No. 2e+03;
 Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 456 RFVGYPGNYHTLFG 469
 ||||:| | :|
 Db 2 RFVGFPDKKHKLGY 15

RESULT 14

ABJ56325
 ID ABJ56325 standard; peptide; 15 AA.

XX
 AC ABJ56325;

XX
 DT 16-OCT-2003 (first entry)
 XX

DE 151P3D4 cancer gene related HLA peptide #14145.

XX
 KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer; cellular immune response; adenocarcinoma; bladder; colorectal; lung; bronchial; breast; carcinoma; human leukocyte antigen; HLA.
 XX

OS Homo sapiens.

XX
 PN WO200283860-A2.

XX
 PD 24-OCT-2002.

XX
 PF 09-APR-2002; 2002WO-US011644.

XX
 PR 10-APR-2001; 2001US-0282739P.

PR 25-APR-2001; 2001US-0286630P.

XX

PA (AGEN-) AGENSYS INC.

XX

PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;

PI Morrison RK, Ge W, Jakobovits A;

XX

DR WPI; 2003-167091/16.

XX

PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.

XX

PS Claim 13; Page 313; 426pp; English.

XX

CC The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a cell that expresses the 151P3D4 protein is modulated. The novel
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoral or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC human leukocyte antigen peptide relating to the 151P3D4 composition of
CC the invention

XX

SQ Sequence 15 AA;

Query Match 1.2%; Score 48; DB 6; Length 15;

Best Local Similarity 57.1%; Pred. No. 2e+03;

Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 456 RFVGYPGNYHTLFG 469

||||:| || :|

Db 2 RFVGFPDKHKLYG 15

RESULT 15

ABJ56284

ID ABJ56284 standard; peptide; 15 AA.

XX

AC ABJ56284;

XX

DT 16-OCT-2003 (first entry)

XX

DE 151P3D4 cancer gene related HLA peptide #14104.

XX

KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoural; cancer;
 KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
 KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.
 XX
 OS Homo sapiens.
 XX
 PN WO200283860-A2.
 XX
 PD 24-OCT-2002.
 XX
 PF 09-APR-2002; 2002WO-US011644.
 XX
 PR 10-APR-2001; 2001US-0282739P.
 PR 25-APR-2001; 2001US-0286630P.
 XX
 PA (AGEN-) AGENSYN INC.
 XX
 PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
 PI Morrison RK, Ge W, Jakobovits A;
 XX
 DR WPI; 2003-167091/16.
 XX
 PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
 PT cellular immune response, or for diagnosing, prognosing, preventing or
 PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
 PT or carcinoma.
 XX
 PS Claim 13; Page 313; 426pp; English.
 XX
 CC The invention relates to a novel composition comprising a substance that
 CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
 CC a molecule that is modulated by the 151P3D4 protein, where the status of
 CC a cell that expresses the 151P3D4 protein is modulated. The novel
 CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
 CC a humoral or cellular immune response. The 151P3D4 genes and proteins
 CC are also useful for diagnosing, prognosing, preventing or treating
 CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
 CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
 CC human leukocyte antigen peptide relating to the 151P3D4 composition of
 CC the invention
 XX
 SQ Sequence 15 AA;

Query Match	1.1%	Score	47	DB	6	Length	15;
Best Local Similarity	57.1%	Pred. No.	2.5e+03;				
Matches	8	Conservative	2	Mismatches	4	Indels	0
Gaps							0;

Qy 457 FVGYPGNYHTLFGV 470
 ||||:| | :|||

Db 1 FVGFPDKHKLYGV 14

Search completed: June 24, 2008, 15:40:57
Job time : 328 secs

SCORE 3.0